Predictive Oncology’s (NASDAQ: POAI) Helomics Exec Talks AI, Big Data and Biology During Podcast Appearance
Convergence of AI, big data and biology allows Helomics to test drugs on living tumor tissue rather than artificial systems Helomics model evaluates multiple measurements in powerful multi-omics approach to cancer research Knowledge encapsulated by Helomics AI is “gold dust,” says chief innovation officer Data, AI and biology come together at Helomics in a way that promises exciting things for the future, according to Mark Collins, PhD and chief technical officer at the company, which is a subsidiary of Predictive Oncology (NASDAQ: POAI) (https://ibn.fm/ms1hL). Collins was a guest speaker on a DojoLIVE! podcast titled “Can We Cure Cancer with Artificial Intelligence?” where…











